De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Nuwellis Beheer

Beheer criteriumcontroles 4/4

De CEO Nuwellis' is Nestor Jaramillo, benoemd in Jul2020, heeft een ambtstermijn van 4.25 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 606.60K, bestaande uit 69.3% salaris en 30.7% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.006% van de aandelen van het bedrijf, ter waarde $ 139.29. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.3 jaar en 4.4 jaar.

Belangrijke informatie

Nestor Jaramillo

Algemeen directeur

US$606.6k

Totale compensatie

Percentage CEO-salaris	69.3%
Dienstverband CEO	4.3yrs
Eigendom CEO	0.006%
Management gemiddelde ambtstermijn	3.3yrs
Gemiddelde ambtstermijn bestuur	4.4yrs

Recente managementupdates

Recent updates

Nuwellis hires Lynn Blake as CFO

Oct 19

Nuwellis surges 90% on positive data from Postoperative Coronary Artery Bypass Grafting treatment

Aug 31

Nuwellis Q2 2022 Earnings Preview

Aug 08

CHF Solutions down 10% on Q3 miss

Nov 10

Analyse CEO-vergoeding

Hoe is Nestor Jaramillo's beloning veranderd ten opzichte van Nuwellis's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$23m
Mar 31 2024	n/a	n/a	-US$20m
Dec 31 2023	US$607k	US$421k	-US$23m
Sep 30 2023	n/a	n/a	-US$17m
Jun 30 2023	n/a	n/a	-US$17m
Mar 31 2023	n/a	n/a	-US$17m
Dec 31 2022	US$715k	US$412k	-US$15m
Sep 30 2022	n/a	n/a	-US$17m
Jun 30 2022	n/a	n/a	-US$18m
Mar 31 2022	n/a	n/a	-US$19m
Dec 31 2021	US$1m	US$384k	-US$20m
Sep 30 2021	n/a	n/a	-US$18m
Jun 30 2021	n/a	n/a	-US$17m
Mar 31 2021	n/a	n/a	-US$17m
Dec 31 2020	US$481k	US$343k	-US$18m
Sep 30 2020	n/a	n/a	-US$19m
Jun 30 2020	n/a	n/a	-US$19m
Mar 31 2020	n/a	n/a	-US$20m
Dec 31 2019	US$639k	US$209k	-US$23m

Compensatie versus markt: De totale vergoeding ($USD 606.60K ) Nestor } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 677.23K ).

Compensatie versus inkomsten: De vergoeding van Nestor is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Nestor Jaramillo (67 yo)

4.3yrs

Tenure

US$606,603

Compensatie

Mr. Nestor Jaramillo, Jr. has been President of Nuwellis, Inc. (formerly known as CHF Solutions, Inc.) since July 1, 2020 and has been its Chief Executive Officer and Director since January 16, 2021 and se...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Nestor Jaramillo	President	4.3yrs	US$606.60k	0.0063% $ 173.2
Robert Scott	Chief Financial Officer	1.1yrs	US$291.41k	0% $ 0
Neil Ayotte	Senior VP	3.3yrs	US$406.49k	0% $ 0
John Kowalczyk	Senior Vice President of Sales & Marketing	2.8yrs	geen gegevens	geen gegevens
Sandra Eayrs	Chief Human Resources Officer	9.8yrs	geen gegevens	geen gegevens
John Jefferies	Chief Medical Officer & Member of Medical Advisory Board	1.8yrs	geen gegevens	geen gegevens
Paul Wotta	Corporate Controller	12.8yrs	geen gegevens	geen gegevens

3.3yrs

Gemiddelde duur

64yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van NUWE wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Nestor Jaramillo	President	3.8yrs	US$606.60k	0.0063% $ 173.2
John Jefferies	Chief Medical Officer & Member of Medical Advisory Board	no data	geen gegevens	geen gegevens
John Erb	Chairman of the Board	12.1yrs	US$65.86k	0% $ 0
Gregory Waller	Independent Director	13.2yrs	US$68.86k	0% $ 0
Michael McCormick	Lead Independent Director	1.4yrs	US$25.66k	0% $ 0
Maria Costanzo	Independent Director & Member of Medical Advisory Board	5.1yrs	US$53.79k	geen gegevens
Archelle Georgiou	Independent Director	less than a year	geen gegevens	0% $ 0
Steven Coca	Member of Medical Advisory Board	no data	geen gegevens	geen gegevens
Daniel Beckles	Member of Medical Advisory Board	no data	geen gegevens	geen gegevens
Maria DeVita	Member of Medical Advisory Board	no data	geen gegevens	geen gegevens
Aroti Hegde	Member of Medical Advisory Board	no data	geen gegevens	geen gegevens
Sitaramesh Emani	Member of Medical Advisory Board	no data	geen gegevens	geen gegevens

4.4yrs

Gemiddelde duur

68yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van NUWE wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.4 jaar).

Nuwellis Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

Less than half of directors are independent

Nuwellis, Inc. Announces Board of Directors Transition

Nuwellis, Inc. Appoints Robert B. Scott as Chief Financial Officer, Effective September 2, 2023

Nuwellis, Inc. Announces the Appointment of Mike Mccormick to its Board of Directors

Nuwellis, Inc. Announces Board Changes

Nuwellis Appoints John Jefferies as Chief Medical Officer

Recent updates

Nuwellis, Inc. has completed a Follow-on Equity Offering in the amount of $0.891783 million.

Nuwellis, Inc. has filed a Follow-on Equity Offering in the amount of $0.916782 million.

Nasdaq Panel Grants Nuwellis Continued Listing on the Nasdaq Stock Market, Subject to Conditions

Nuwellis Announces First Pediatric Patient Treated in A Commercial Setting with Seastar Medical's Quelimune Therapy At Cincinnati Children's

Nuwellis, Inc. has filed a Follow-on Equity Offering in the amount of $1.990002 million.

Nuwellis, Inc. to Report Q2, 2024 Results on Aug 13, 2024

Nuwellis Marks First Commercial Sale of Quelimune Therapy to Cincinnati Children's

Nuwellis, Inc. Announces New Clinical Evidence Demonstrating the Efficacy of its Aquadex® System to be Presented at HFSA 2024 Conference

Nuwellis Receives Non-Compliance Letter from Nasdaq Regarding Minimum Stockholders' Equity Requirement

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Nuwellis, Inc. Receives USPTO Notice of Patent Allowance for Innovative Pediatric CRRT Technology

Nuwellis, Inc. to Report Q1, 2024 Results on May 07, 2024

Nuwellis, Inc. Announces Launch of Ultrafiltration Therapy Using Aquadex Smartflow® System at Henry Ford Health

Consensus EPS estimates upgraded to US$2.69 loss

Nuwellis, Inc. Announces Results from Two New Clinical Data Analyses from the AVOID-HF Trial, Which Demonstrate the Benefits of its Aquadex System in Reducing Heart Failure Readmissions at 30 Days

Full year 2023 earnings: EPS exceeds analyst expectations

Nuwellis, Inc. to Report Q4, 2023 Results on Mar 05, 2024

New major risk - Share price stability

Nuwellis, Inc. Receives FDA Clearance for an Additional Dual Lumen Extended Length Peripheral Catheter

Nuwellis Receives Non-Compliance Notice from Nasdaq

Nuwellis, Inc. Announces New Real-World Data Highlight the Clinical Benefits of Ultrafiltration Therapy with Hematocrit Monitoring Foriatric Patients

Price target decreased by 36% to US$6.00

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Revenue and earnings growth

Less than half of directors are independent

Nuwellis, Inc. Announces Board of Directors Transition

Nuwellis, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Nuwellis, Inc. has completed a Composite Units Offering in the amount of $2.25 million.

Nuwellis Provides Regulatory Update on Seastar Medical's Selective Cytopheretic Device Use in Pediatric Acute Kidney Injury Under A Humanitarian Device Exemption

New major risk - Share price stability

Nuwellis, Inc. Appoints Robert B. Scott as Chief Financial Officer, Effective September 2, 2023

Second quarter 2023 earnings released: US$3.65 loss per share (vs US$40.67 loss in 2Q 2022)

Nuwellis, Inc. to Report Q2, 2023 Results on Aug 08, 2023

New major risk - Revenue and earnings growth

Nuwellis, Inc. Announces the Appointment of Mike Mccormick to its Board of Directors

Consensus revenue estimates fall by 19%

Price target decreased by 27% to US$16.00

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates upgraded to US$13.08 loss

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Nuwellis, Inc. to Report Q4, 2022 Results on Feb 28, 2023

Nuwellis, Inc. Announces Board Changes

Nuwellis, Inc. Provides Preliminary Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

Nuwellis Appoints John Jefferies as Chief Medical Officer

Nuwellis Announces Compliance with Nasdaq Listing Requirements

Nuwellis, Inc. Receives 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement

Price target decreased to US$2.17

Insufficient new directors

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Nuwellis, Inc. Announces Peer Reviewed Data Demonstrating 71% Survival with Kidney Replacement Therapy Using A Modified Aquadex in Low-Birth-Weight Preterm Neonates

Insufficient new directors

Consensus forecasts updated

Nuwellis, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Nuwellis hires Lynn Blake as CFO

Nuwellis, Inc. Provides Product Revenue Guidance for the Three Months Ended September 30, 2022

Nuwellis Announces Data Demonstrating Statistically Superior Clinical Benefit of Aquadex Therapy in Reducing Heart Failure Events and Mortality At the 2022 Hfsa Meeting

Insufficient new directors

Nuwellis, Inc. Announces the Activation of New Sites for Its Pivotal REVERSE-HF Trial

Nuwellis, Inc. Announces Executive Changes

Nuwellis, Inc. Announces New Clinical Data Demonstrating 100% Survival at 30 Days Following Use of Ultrafiltration in High-Risk Postoperative Coronary Artery Bypass Grafting (CABG) Patients

Nuwellis surges 90% on positive data from Postoperative Coronary Artery Bypass Grafting treatment

Nuwellis, Inc. Announces U.S. Patent and Trademark Office Awards Patent for Innovative Pediatric Technology

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Nuwellis Q2 2022 Earnings Preview

Nuwellis, Inc Announces the Submission of the AVOID-HF Clinical Analysis as a Late Breaking Clinical Trial at HFSA

Nuwellis, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Nuwellis, Inc. Announces First Patient Enrolled in Its Pivotal Trial REVERSE-HF

Nuwellis Receives a Letter from the Listing Qualifications Department of Nasdaq Regarding Minimum Bid Price Requirement

First quarter 2022 earnings: EPS and revenues exceed analyst expectations